Norikazu Sakakibara1, Masanori Baba2, Mika Okamoto2, Masaaki Toyama2, Yosuke Demizu3, Takashi Misawa3, Masaaki Kurihara3, Kohji Irie4, Yoshihisa Kato4, Tokumi Maruyama4. 1. Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki City, Kagawa, Japan bara@kph.bunri-u.ac.jp. 2. Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 3. Division of Organic Chemistry, National Institute of Health Sciences, Setagaya, Tokyo, Japan. 4. Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki City, Kagawa, Japan.
Abstract
BACKGROUND: A new series of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives were synthesized and evaluated as non-nucleoside HIV-1 reverse transcriptase inhibitors. METHODS: A series of new 6-azido and 6-amino derivatives of 1-substituted-3-(3,5-dimethylbenzyl)uracils were synthesized using our previously reported method, and three acyclic derivatives were synthesized from urea. The anti-HIV-1 activities of these compounds were determined based on the inhibition of virus-induced cytopathogenicity in MT-4 cells. The cytotoxicities of the compounds were evaluated using the viability of mock-infected cells. RESULTS: Some of these compounds showed good-to-moderate activities against HIV-1 with half maximal effective concentration (EC50) values in the submicromolar or subnanomolar range. Compared with emivirine, compound 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil showed significant anti-HIV-1 activity with an EC50 value of 10 nM and a high selectivity index of 1923. Preliminary structure-activity relationship studies and molecular modeling analyses were carried out to explore the major interactions between HIV-1 reverse transcriptase and the potent inhibitor 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil; these results may be important for further development of this class of compounds as anti-HIV-1 agents. CONCLUSION: The excellent activity of 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil (EC50: 0.010 ± 0.006 µM, SI: >1923) may serve as the basis for conducting further investigations on the behavior of this class of compounds against drug-resistant mutants.
BACKGROUND: A new series of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives were synthesized and evaluated as non-nucleoside HIV-1 reverse transcriptase inhibitors. METHODS: A series of new 6-azido and 6-amino derivatives of 1-substituted-3-(3,5-dimethylbenzyl)uracils were synthesized using our previously reported method, and three acyclic derivatives were synthesized from urea. The anti-HIV-1 activities of these compounds were determined based on the inhibition of virus-induced cytopathogenicity in MT-4 cells. The cytotoxicities of the compounds were evaluated using the viability of mock-infected cells. RESULTS: Some of these compounds showed good-to-moderate activities against HIV-1 with half maximal effective concentration (EC50) values in the submicromolar or subnanomolar range. Compared with emivirine, compound 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil showed significant anti-HIV-1 activity with an EC50 value of 10 nM and a high selectivity index of 1923. Preliminary structure-activity relationship studies and molecular modeling analyses were carried out to explore the major interactions between HIV-1 reverse transcriptase and the potent inhibitor 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil; these results may be important for further development of this class of compounds as anti-HIV-1 agents. CONCLUSION: The excellent activity of 6-amino-3-(3,5-dimethylbenzyl)-1-(4-aminobenzyl)uracil (EC50: 0.010 ± 0.006 µM, SI: >1923) may serve as the basis for conducting further investigations on the behavior of this class of compounds against drug-resistant mutants.
Authors: H Tanaka; M Baba; S Saito; T Miyasaka; H Takashima; K Sekiya; M Ubasawa; I Nitta; R T Walker; H Nakashima Journal: J Med Chem Date: 1991-04 Impact factor: 7.446
Authors: A L Hopkins; J Ren; R M Esnouf; B E Willcox; E Y Jones; C Ross; T Miyasaka; R T Walker; H Tanaka; D K Stammers; D I Stuart Journal: J Med Chem Date: 1996-04-12 Impact factor: 7.446
Authors: Jingshan Ren; Charles E Nichols; Anna Stamp; Phillip P Chamberlain; Robert Ferris; Kurt L Weaver; Steven A Short; David K Stammers Journal: FEBS J Date: 2006-08 Impact factor: 5.542
Authors: J H Chan; J S Hong; R N Hunter ; G F Orr; J R Cowan; D B Sherman; S M Sparks; B E Reitter; C W Andrews ; R J Hazen; M St Clair; L R Boone; R G Ferris; K L Creech; G B Roberts; S A Short; K Weaver; R J Ott; J Ren; A Hopkins; D I Stuart; D K Stammers Journal: J Med Chem Date: 2001-06-07 Impact factor: 7.446
Authors: Vasily A Kezin; Elena S Matyugina; Mikhail S Novikov; Alexander O Chizhov; Robert Snoeck; Graciela Andrei; Sergei N Kochetkov; Anastasia L Khandazhinskaya Journal: Molecules Date: 2022-04-30 Impact factor: 4.927